HK79390A - Pharmaceutical compositions containing pharmacologically active biphosphonates - Google Patents

Pharmaceutical compositions containing pharmacologically active biphosphonates

Info

Publication number
HK79390A
HK79390A HK793/90A HK79390A HK79390A HK 79390 A HK79390 A HK 79390A HK 793/90 A HK793/90 A HK 793/90A HK 79390 A HK79390 A HK 79390A HK 79390 A HK79390 A HK 79390A
Authority
HK
Hong Kong
Prior art keywords
biphosphonates
pharmaceutical compositions
compositions containing
pharmacologically active
containing pharmacologically
Prior art date
Application number
HK793/90A
Other languages
English (en)
Inventor
Sergio Rosini
Giorgio Staibano
Original Assignee
Gentili Ist Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK79390(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentili Ist Spa filed Critical Gentili Ist Spa
Publication of HK79390A publication Critical patent/HK79390A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK793/90A 1982-04-15 1990-10-03 Pharmaceutical compositions containing pharmacologically active biphosphonates HK79390A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Publications (1)

Publication Number Publication Date
HK79390A true HK79390A (en) 1990-10-12

Family

ID=11171970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK793/90A HK79390A (en) 1982-04-15 1990-10-03 Pharmaceutical compositions containing pharmacologically active biphosphonates

Country Status (12)

Country Link
US (1) US4621077A (it)
JP (1) JPS58189193A (it)
BE (1) BE896453A (it)
CH (1) CH661437A5 (it)
FR (1) FR2525223B1 (it)
GB (1) GB2118042B (it)
HK (1) HK79390A (it)
IT (1) IT1201087B (it)
LU (2) LU84746A1 (it)
MX (1) MX9203428A (it)
NL (5) NL192562C (it)
SE (1) SE463239B (it)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (fi) * 1989-09-08 1991-08-12 Huhtamaeki Oy Foerfarande foer framstaellning av metylenbisfosfonsyror.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) * 1990-09-18 1992-03-25 Merck & Co Inc Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
IT1247034B (it) * 1991-06-26 1994-12-12 Gentili Ist Spa Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (it) * 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
WO1996025165A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
US5914099A (en) * 1995-05-12 1999-06-22 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
JPH11506757A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 二ナトリウムアレンドロネート製剤
WO1996039107A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
EP1007054A4 (en) * 1996-10-04 2000-07-19 Merck & Co Inc LIQUID ALENDRONATE FORMULATIONS
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6410782B1 (en) * 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6416964B2 (en) 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
AU757104B2 (en) 1998-06-24 2003-01-30 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US6281381B1 (en) * 1998-08-27 2001-08-28 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
HUP0200342A3 (en) * 1999-02-17 2005-02-28 Teva Pharma Novel process for preparing alendronic acid
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
SE9903345D0 (sv) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
SK2532004A3 (en) * 2001-12-21 2004-11-03 Procter & Gamble Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
CA2485443C (en) * 2002-05-17 2010-04-06 Teva Pharmaceutical Industries Ltd Use of aromatic hydrocarbons and silicone fluids for making bisphosphonic acids
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
SG174628A1 (en) * 2002-12-20 2011-10-28 Hoffmann La Roche High dose ibandronate formulation
US20040206932A1 (en) 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (zh) * 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP2279722B1 (en) * 2003-08-12 2013-05-01 3M Innovative Properties Company Self-etching dental compositions and its use
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
SI1753395T1 (sl) 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enterične trdne formulacije oralnih odmerkov bifosfonata, ki vsebuje kelirno sredstvo
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
AU2005269869B2 (en) 2004-07-08 2011-12-01 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
JP5037342B2 (ja) 2004-08-11 2012-09-26 スリーエム イノベイティブ プロパティズ カンパニー 複数の酸性化合物を含む粘着性組成物
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
CN101198316A (zh) * 2005-03-17 2008-06-11 伊兰制药国际有限公司 纳米微粒双膦酸盐组合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
WO2007101415A2 (de) 2006-02-03 2007-09-13 Universität Stuttgart - Institut für Chemische Verfahrenstechnik Phosphonsäure-haltige blends und phosphonsäure-haltige polymere
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
CN101522032A (zh) * 2006-11-21 2009-09-02 帝国制药美国公司 二膦酸吸入制剂及其使用方法
EP2101716A2 (en) 2006-12-13 2009-09-23 3M Innovative Properties Company Methods of using a dental composition having an acidic component and a photobleachable dye
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2240159A2 (en) * 2008-02-05 2010-10-20 Actavis Group PTC EHF Alendronate formulations, method of making and method of use thereof
US7964584B2 (en) * 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
WO2013019874A1 (en) 2011-08-01 2013-02-07 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143123A (en) * 1966-05-18 1969-02-19 Albright & Wilson Mfg Ltd Phosphate compositions
GB1235029A (en) * 1966-12-29 1971-06-09 Procter & Gamble Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) * 1972-06-08 1976-04-13 M Francis Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) * 1972-06-30 1977-10-26 Procter & Gamble Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
IE39282B1 (en) * 1973-05-23 1978-09-13 Procter & Gamble Radionuclide labelled phosphonic acids for the treatment of calcific tumors
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
US4216211A (en) * 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) * 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (it) * 1978-06-27 1985-08-31 Gentili Ist Spa Composizione farmaceutica per la terapia dell'ittero ostruttivo non neoplastico
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
US4254114A (en) * 1979-01-02 1981-03-03 The Proctor & Gamble Company Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
GB2076889B (en) * 1980-03-12 1983-10-26 Cadbury Schweppes Transport Feeding fuel and water emulsion i c engines
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
GB2079285B (en) * 1980-07-09 1984-05-23 Symphar Sa Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) * 1980-08-27 1982-03-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) * 1980-09-29 1982-04-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (fr) * 1980-10-07 1982-03-22 Procter & Gamble Procede d'inhibition des metastases de cellules tumorales
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie

Also Published As

Publication number Publication date
GB8308791D0 (en) 1983-05-11
LU88714I2 (fr) 1996-08-23
SE8302130L (sv) 1983-10-16
NL970038I2 (nl) 2000-11-01
NL970038I1 (nl) 1998-01-05
NL192562B (nl) 1997-06-02
NL980010I1 (nl) 1998-05-06
NL192562C (nl) 1997-10-03
FR2525223B1 (fr) 1986-04-25
US4621077A (en) 1986-11-04
GB2118042A (en) 1983-10-26
SE463239B (sv) 1990-10-29
MX9203428A (es) 1992-07-01
SE8302130D0 (sv) 1983-04-15
BE896453A (fr) 1983-08-01
GB2118042B (en) 1986-01-15
JPS58189193A (ja) 1983-11-04
NL980005I1 (nl) 1998-04-01
FR2525223A1 (fr) 1983-10-21
IT1201087B (it) 1989-01-27
LU84746A1 (fr) 1983-11-17
CH661437A5 (it) 1987-07-31
NL980004I1 (nl) 1998-04-01
IT8220781A0 (it) 1982-04-15
NL8301324A (nl) 1983-11-01
JPH0213645B2 (it) 1990-04-04

Similar Documents

Publication Publication Date Title
HK79390A (en) Pharmaceutical compositions containing pharmacologically active biphosphonates
GB8326565D0 (en) Pharmaceutical compositions
GB8327612D0 (en) Pharmaceutical compositions
DE3367849D1 (en) Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or -4-one derivatives
ZA834074B (en) Pharmaceutical composition
ZA833781B (en) Pharmaceutical compositions
EP0093551A3 (en) Pharmaceutical composition
GB2118176B (en) Pharmaceutical compositions
GB2117766B (en) Pharmaceutical compositions
ZA836703B (en) Pharmaceutical compositions
GB8429749D0 (en) Pharmaceutical compositions
GB8313814D0 (en) Pharmaceutical compositions
GB8329700D0 (en) Anti-haemophilic pharmaceutical composition
DE3377696D1 (en) Pharmaceutical compositions
US4594359B1 (en) Pharmaceutical compositions
GB8328896D0 (en) Pharmaceutical composition
GB2114001B (en) Nasel pharmaceutical compositions
GB8305028D0 (en) Pharmaceutical compositions
GB8314736D0 (en) Pharmaceutical compositions
GB8330810D0 (en) Pharmaceutical compositions
GB8332653D0 (en) Pharmaceutical composition
GB8331068D0 (en) Pharmaceutical compositions
GB8329391D0 (en) Pharmaceutical compositions
GB8314540D0 (en) Pharmaceutical composition
DE3372706D1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PE Patent expired